Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768310.793547377 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41179 ◽

2020 ◽

Vol 72 (5) ◽

pp. 761-768 ◽

Cited By ~ 10

Author(s):

Ronald F. Vollenhoven ◽

Bevra H. Hahn ◽

George C. Tsokos ◽

Peter Lipsky ◽

Kaiyin Fei ◽

...

Keyword(s):

Phase Ii ◽

Lupus Erythematosus ◽

Crossover Trial ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

One Year

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

10.1136/annrheumdis-2012-202760 ◽

2013 ◽

Vol 73 (1) ◽

pp. 183-190 ◽

Cited By ~ 161

Author(s):

Daniel J Wallace ◽

Kenneth Kalunian ◽

Michelle A Petri ◽

Vibeke Strand ◽

Frederic A Houssiau ◽

...

Keyword(s):

Multicentre Study ◽

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

10.1136/annrheumdis-2015-207654 ◽

2015 ◽

Vol 75 (2) ◽

pp. 332-340 ◽

Cited By ~ 111

Author(s):

J T Merrill ◽

R F van Vollenhoven ◽

J P Buyon ◽

R A Furie ◽

W Stohl ◽

...

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

10.1136/annrheumdis-2015-207653 ◽

2015 ◽

Vol 75 (2) ◽

pp. 323-331 ◽

Cited By ~ 113

Author(s):

D A Isenberg ◽

M Petri ◽

K Kalunian ◽

Y Tanaka ◽

M B Urowitz ◽

...

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717976439.793474960 ◽

2013 ◽

Author(s):

Joan Merrill

Keyword(s):

Multicentre Study ◽

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

Rheumatology and Therapy ◽

10.1007/s40744-021-00351-7 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Dale Wright ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Post Hoc

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

10.1136/annrheumdis-2018-213032 ◽

2018 ◽

Vol 77 (6) ◽

pp. 883-889 ◽

Cited By ~ 33

Author(s):

Joan T Merrill ◽

William R Shanahan ◽

Morton Scheinberg ◽

Kenneth C Kalunian ◽

David Wofsy ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Selective Inhibitor ◽

Phase Iii ◽

Systemic Lupus ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

B Cell Activating Factor

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Rheumatology and Therapy ◽

10.1007/s40744-021-00353-5 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

Richard A. Furie

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Systemic Lupus ◽

Double Blind ◽